These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 25473153)

  • 1. Risk of infections associated with biological treatment in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
    McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
    Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Shukla T; Singh S; Tandon P; McCurdy JD
    J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
    Shale MJ; Seow CH; Coffin CS; Kaplan GG; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2010 Jan; 31(1):20-34. PubMed ID: 19681818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of infections with biological agents.
    Kopylov U; Afif W
    Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nocardia infections among immunomodulated inflammatory bowel disease patients: A review.
    Abreu C; Rocha-Pereira N; Sarmento A; Magro F
    World J Gastroenterol; 2015 Jun; 21(21):6491-8. PubMed ID: 26074688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non tuberculous anti-TNF associated opportunistic infections].
    Marie I; Guglielmino E
    Rev Med Interne; 2010 May; 31(5):353-60. PubMed ID: 20381217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
    Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
    Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.
    Ford AC; Peyrin-Biroulet L
    Am J Gastroenterol; 2013 Aug; 108(8):1268-76. PubMed ID: 23649185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
    Winthrop KL
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sickness, encephalitis and other complications of anti-cytokine therapy.
    Vermeire S; Van Assche G; Rutgeerts P
    Best Pract Res Clin Gastroenterol; 2009; 23(1):101-12. PubMed ID: 19258190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
    Miehsler W; Novacek G; Wenzl H; Vogelsang H; Knoflach P; Kaser A; Dejaco C; Petritsch W; Kapitan M; Maier H; Graninger W; Tilg H; Reinisch W;
    J Crohns Colitis; 2010 Sep; 4(3):221-56. PubMed ID: 21122513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of infections of biological therapies with accent on inflammatory bowel disease.
    Nanau RM; Cohen LE; Neuman MG
    J Pharm Pharm Sci; 2014; 17(4):485-531. PubMed ID: 25579431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.